One of the first clinically relevant human cancer model cell lines engineered with CRISPR/Cas9 involved a fusion between an echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) [termed as the EML4/ALK oncogenic fusion] that was engineered in non-small cell lung cancer (NSCLC) adenocarcinoma [61]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.